Patents Examined by Thaian N. Ton
  • Patent number: 10844402
    Abstract: A gene expression system is provided. The system comprises at least one coding sequence to be expressed in an organism, and at least one promoter operably linked thereto. It further comprises at least one splice control sequence which, in cooperation with a spliceosome, mediates alternative splicing of RNA transcripts of the coding sequence. The mediation of alternative splicing is in a sex-specific, stage-specific, germline-specific and tissue-specific manner.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: November 24, 2020
    Assignee: Oxitec Limited
    Inventor: Luke Alphey
  • Patent number: 10842826
    Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblast in hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically. T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: November 24, 2020
    Assignees: IMSTEM BIOTECHNOLOGY, INC., UNIVERSITY OF CONNECTICUT
    Inventors: Xiaofang Wang, Ren-He Xu
  • Patent number: 10836832
    Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: November 17, 2020
    Assignee: ABLEXIS, LLC
    Inventors: Larry Green, Hiroaki Shizuya
  • Patent number: 10829564
    Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: November 10, 2020
    Assignee: ABLEXIS, LLC
    Inventors: Larry Green, Hiroaki Shizuya
  • Patent number: 10829733
    Abstract: Compositions and processes for culturing human stem cells in vitro in an undifferentiated state are disclosed. In this regard, human embryonic stem cells proliferated and maintained their pluripotency when cultured on plates coated with recombinant laminin-10 (laminin-511).
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: November 10, 2020
    Assignee: BIOLAMINA AB
    Inventors: Karl Tryggvason, Sergey Rodin, Anna Domogatskaya
  • Patent number: 10827730
    Abstract: Non-human animals and offspring thereof comprising at least one modified chromosomal sequence in a gene encoding a CD163 protein are provided. Animal cells that contain such modified chromosomal sequences are also provided. The animals and cells have increased resistance to pathogens, including porcine reproductive and respiratory syndrome virus (PRRSV). The animals and offspring have chromosomal modifications of a CD163 gene. The invention further relates to methods of breeding to create pathogen-resistant animals and populations of animals made using such methods.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: November 10, 2020
    Assignee: The Curators of the University of Missouri
    Inventors: Randall S. Prather, Kevin D. Wells, Kristin M. Whitworth
  • Patent number: 10820582
    Abstract: Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Ig? light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Ig? light chains, in whole or in part, that are encoded by human Ig? light chain-encoding sequences inserted into an endogenous Ig? light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: November 3, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Chunguang Guo, Faith Harris, Vera Voronina, John McWhirter, Natasha Levenkova, Lynn Macdonald, Naxin Tu, Andrew J. Murphy
  • Patent number: 10815458
    Abstract: Compositions and methods of activating dendritic cells with LMP1 and LMP1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. LMP1 or LMP1-CD40 chimeric protein may be used to activate and mature dendritic cells. LMP1 and LMP1-activated dendritic cells act as an adjuvant to enhance the cellular immune response. Also disclosed herein are kits for activating dendritic cells and for preparing a vaccine formulation. Administration of the dendritic cells transfected with LMP1 can induce an immune response against cancer or infection. The mature dendritic cells may comprise an antigen and at least one cytokine in addition to LMP1. Use of LMP1 or LMP1-CD40 provides a way to activate and mature dendritic cells that retain functional and migratory abilities without the side effects that result from maturing the dendritic cells using PGE2.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: October 27, 2020
    Assignee: UNIVERSITY OF MIAMI
    Inventor: Geoffrey William Stone
  • Patent number: 10813987
    Abstract: The subject technology relates generally to compositions and methods for producing plasmid DNA of a desired quality. In addition, it relates to the discovery of Escherichia coli (E. coli) bacteria with a constitutive methylase gene stably incorporated into the chromosomal DNA and uses thereof.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: October 27, 2020
    Assignee: Loma Linda University
    Inventor: Alan P. Escher
  • Patent number: 10813346
    Abstract: The invention provides compositions and methods for enhanced production of immunoglobulin diversity. Specifically, the invention provides compositions and methods for making accessible a B cell receptor repertoire that has not been culled by developmental tolerance mechanisms. The invention also provides transgenic animals, cells, and antibodies resulting from these compositions and methods.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: October 27, 2020
    Assignee: TRIANNI, INC.
    Inventors: Matthias Wahl, Bao Duong, Nigel Killeen
  • Patent number: 10799474
    Abstract: The present invention provides a method for treating leukemia utilizing somatic cell reprogramming. The method includes a step of introduction of somatic cell reprogramming inducing factors Oct-4, Sox-2, Klf4 and c-Myc (OSKM for short) into leukemic cells or a step of utilizing small reprogramming molecules in in-vitro culture. It promotes leukemic cells to initiate process of somatic cell reprogramming in order to induce apoptosis and finally purpose of eliminating leukemic cells in-vivo or in-vitro is achieved. It provides new ideas and methods for clinical treatment of leukemia in the future.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 13, 2020
    Assignee: Institute of Hematology and Blood Disease Hospital, CAMS & PUMC
    Inventors: Tao Cheng, Hui Cheng, Yajie Wang, Hongyan Zhang, Yawei Zheng, Sha Hao
  • Patent number: 10793833
    Abstract: The disclosure provides methods and compositions useful for obtaining induced stem cells, methods of making and use thereof.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: October 6, 2020
    Assignee: The Regents of the University of California
    Inventors: Steven F. Dowdy, Naohisa Yoshioka
  • Patent number: 10793829
    Abstract: The present invention relates to transgenic mammals that express bovine-based immunoglobulins, including transgenic rodents that express bovine-based immunoglobulins for the development of bovine therapeutic antibodies.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: October 6, 2020
    Assignee: TRIANNI, INC.
    Inventor: Matthias Wabl
  • Patent number: 10792329
    Abstract: The present invention relates to S100 protein and nuclei acids encoding S100 protein for enhancing the cardiac power as well as vectors and pharmaceuticals comprising the same and uses thereof.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: October 6, 2020
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Hugo Katus, Patrick Most
  • Patent number: 10791722
    Abstract: Embodiments provided herein relate to systems for synthetically-engineered reciprocal chromosomal translocation for gene insertion into a population of organisms such as insects.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: October 6, 2020
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Bruce A. Hay, Omar S. Akbari, Anna B. Buchman
  • Patent number: 10793850
    Abstract: The present invention relates to a method for carrying out recombination at a target locus.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: October 6, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Nathalie Wiessenhaan, Catharina Petronella Antonia Maria Kolen, Bernard Meijrink, Viktor Marius Boer, Johannes Andries Roubos, Yvonne Johannes Odilia Arendsen
  • Patent number: 10793874
    Abstract: Methods and compositions are provided for generating targeted genetic modifications on the Y chromosome or a challenging target locus. Compositions include an in vitro culture comprising an XY pluripotent and/or totipotent animal cell (i.e., XY ES cells or XY iPS cells) having a modification that decreases the level and/or activity of an Sry protein; and, culturing these cells in a medium that promotes development of XY F0 fertile females. Such compositions find use in various methods for making a fertile female XY non-human mammal in an F0 generation.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: October 6, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Gustavo Droguett, Anthony Gagliardi, Junko Kuno, Wojtek Auerbach, David Valenzuela
  • Patent number: 10786534
    Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: September 29, 2020
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory A. Bird
  • Patent number: 10787645
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 29, 2020
    Assignee: TILT Biotherapeutics Oy
    Inventors: Akseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
  • Patent number: 10785968
    Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: September 29, 2020
    Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
    Inventors: Richard Flavell, Till Strowig, Markus G. Manz, Chiara Borsotti, Madhav Dhodapkar, Andrew J. Murphy, Sean Stevens, George D. Yancopoulos